Flow Cytometer to Extend Laboratory Capabilities

描述（由申请人提供）：细胞分析设施（CAF），内布拉斯加大学医学中心（UNMC）的核心设施，正在申请581，998.00美元购买高端流式细胞仪，用于分析多参数研究样本。该仪器将是由BD Bioscience根据我们的质量标准制造的6激光器、19检测器LSR II流式细胞仪。现有的LSR II是100%订购的，是实验室中唯一的分析仪器，可用于该地区同时使用6个以上参数的实验，并且没有备份。由于基础和临床研究项目的研究人员对该仪器的需求很高，因此样本处理的延迟是目前的一个问题。这种仪器的停机时间虽然很少，但可能对这些调查人员产生灾难性的影响。拟议的仪器将安置在CAF中，并由经验丰富的人员管理，包括负责人Kuszynski博士，他为该机构提供专门的支持。确定的主要用户组包括9名NIH资助的研究者和一个确定的两人小组，他们需要大部分当前仪器时间（1168小时，数据未显示），将他们的工作转移到新仪器将允许他们和目前使用现有LSR II的其他用户扩展对仪器的访问。LSRII目前的用户总数为31个，包括主要和次要用户，2010年有85名独立调查员使用了该设施。该仪器的加入将促进再生医学、转化研究和癌症生物学领域的进步，以及免疫学、微生物学和艾滋病的进一步基础研究。这些领域的发现将为患者带来更好的治疗，治愈和结果。

DESCRIPTION (provided by applicant): The Cell Analysis Facility (CAF), a core facility of the University of Nebraska Medical Center (UNMC), is requesting $581,998.00 to purchase a high end flow cytometer for the analysis of multi-parametric research samples. This instrument will be a 6 laser, 19 detector LSR II flow cytometer manufactured by BD Bioscience according to our specifications. The existing LSR II is 100% subscribed and is the only analysis instrument in the laboratory available for experiments utilizing more that 6 simultaneous parameters in the area and is without backup. Delays in sample processing are currently an issue as the instrument is in high demand from investigators with both basic and clinical research programs. Down time, though rare, for this instrument could have disastrous implications for these investigators. The proposed instrument will be housed in the CAF and managed by experienced personnel including the director, Dr. Kuszynski who provides dedicated support for the facility. The identified Major User Group consists of nine NIH funded investigators and an identified minor group of two who require most of the current instrument time (1168 hrs, data not shown) and shifting their work to the new instrument will allow for expanded access to the instrumentation for them and additional users who currently use the existing LSR II. The total number of current users for the LSRII is 31 including the major and minor users and 85 independent investigators have used the facility in 2010. Addition of this instrument to the laboratory will foster advances n the areas of regenerative medicine, translational research, and cancer biology as well as further basic research in immunology, microbiology and AIDS. Discoveries in these areas will lead to better treatments, cures and outcomes for patients.